Nanostring Unveils Its Molecular Diagnostics Strategy

One strategy for growth among analytical platform companies is to leverage its instrumentation sales channel by developing or acquiring diagnostics content. Nanostring is now doing this by in-licensing a gene expression signature for breast tumor typing. And unlike other molecular tests for guiding breast cancer therapy, which are performed in specialty CLIA labs run by their developers, this one will be broadly distributed to hospitals and pathology laboratories globally.

Writing in IN VIVO in December 2009, analysts from Leerink Swann pointed to NanoString Technologies Inc. as one of a handful of analytical assay platform companies to have established themselves in the research area and then grown by developing or acquiring novel content for clinical diagnostics. ( See "Leveraging Assay Platforms To Create Category-Killer Diagnostic Tests," IN VIVO , December 2009 Also see "Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests " - In Vivo, 1 December, 2009..) At the time, NanoString had not disclosed the specific nature of those tests. But the start-up had begun discussions with a group of academic collaborators who had formed a company, Bioclassifier LLC, to license a gene expression signature for "intrinsically subtyping" breast tumors. The Bioclassifier team had been working on establishing the clinical utility of its test, called PAM50, for the better part of a decade, using microarrays and quantitative PCR (qPCR) technologies. Now, NanoString will commercialize PAM50 to run on its nCounter analysis system. And unlike other molecular diagnostic tests for guiding breast cancer therapy, such as Genomic Health Inc.'s Oncotype Dx or Agendia BV's MammaPrint, which are performed in specialty CLIA labs run by their developers, PAM50 will be broadly distributed to hospitals and pathology laboratories globally.

nCounter analyzes individual molecules in a single reaction without the need for amplification, using a digital gene expression technology developed...

More from Archive

More from Medtech Insight

Device Sterilization Plants Get Extra 2 Years To Comply On EtO Phase-Out

 
• By 

The exemption, which President Donald Trump announced on July 17, is intended to cut the risk of critical device shortages. Stakeholders say the technology needed to cut emissions to required levels is not yet widely available.

Numerous Injuries Prompt Class I Recall Of Dexcom CGM Receivers

 

Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.

J&J Bets On Robotics, Cardiovascular To Grow Medtech As Tariff Hit Eases, US Manufacturing Grows

 
• By 

Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.